RxDoctor Payments Data

Andres Deik Acosta Madiedo, MD

Neurology · Philadelphia, PANPI 1396907143

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 44.9% of the total.

$32,995in general payments, 2019–2025

Across 68 payments — averaging $485.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$15K
  • MDD US Operations, LLC$5K
  • AbbVie$3K
  • Acorda Therapeutics, Inc$3K
  • Abbott$2K
  • Medtronic$2K
  • plus $2K from 4 others
$1,724,669in research payments, 2019–2025

Across 214 payments — averaging $8059.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$605K
  • Eli Lilly$412K
  • Sunovion Pharmaceuticals Inc.$239K
  • H. Lundbeck A S$219K
  • Biohaven Pharmaceuticals, Inc.$104K
  • Amylyx Pharmaceuticals, Inc.$63K
  • plus $82K from 2 others

What the payments were for

  • Consulting fees$18,15955%
  • Speaking & faculty fees$5,00015%
  • Travel & lodging$7,62223%
  • Food & beverage$2,1827%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,995 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$103,909
Medicare patients
461
Services billed
1,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl228$689,800
RytaryCarbidopa/Levodopa236$471,656
NuplazidPimavanserin Tartrate36$227,594
NeuproRotigotine94$124,726
NourianzIstradefylline30$84,849
AustedoDeutetrabenazine20$71,227
Carbidopa-LevodopaCarbidopa/Levodopa990$51,522
XadagoSafinamide Mesylate38$48,028
Rasagiline Mesylate132$23,268
Pramipexole ErPramipexole Di-Hcl41$20,204
Entacapone100$19,939
InbrijaLevodopa16$19,555
Selegiline Hcl157$17,313
Ropinirole ErRopinirole Hcl91$16,118
Carbidopa-Levodopa ErCarbidopa/Levodopa225$15,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$5,498$689,800228 claims
Amneal Pharmaceuticals LLCRytary, Crexont, Pyridostigmine Bromide$14,831$481,468277 claims
Teva Pharmaceuticals USA, Inc.Austedo$153$71,22720 claims
Acorda Therapeutics, IncInbrija$2,825$19,55516 claims
AbbVieBotox$3,435$12,31912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →